SILIMARIN 200 mg compresse rivestite, Kisqali 200 mg film-coated tablets clinical trials

Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimarin.

This study looks at whether a natural product called Silymarin can help protect the liver of breast cancer patients taking a medicine called Ribociclib. It aims to see if Silymarin can reduce liver side effects, comparing it to what we know from past studies.